PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements.

Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-0135, USA.
Journal of Nuclear Medicine (Impact Factor: 5.56). 04/2006; 47(3):520-7.
Source: PubMed

ABSTRACT 18F-2beta-Carbomethoxy-3beta-(4-chlorophenyl)-8-(2-fluoroethyl)nortropane (18F-FECNT), a PET radioligand for the dopamine transporter (DAT), generates a radiometabolite that enters the rat brain. The aims of this study were to characterize this radiometabolite and to determine whether a similar phenomenon occurs in human and nonhuman primate brains by examining the stability of the apparent distribution volume in DAT-rich (striatum) and DAT-poor (cerebellum) regions of the brain.
Two rats were infused with 18F-FECNT and sacrificed at 60 min. Extracts of brain and plasma were analyzed by high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometric (LC-MS) techniques. Two human participants and 3 rhesus monkeys were injected with 18F-FECNT and scanned kinetically, with serial arterial blood analysis.
At 60 min after the injection of rats, 18F-FECNT accumulated to levels about 7 times higher in the striatum than in the cortex and cerebellum. The radiometabolite was distributed at equal concentrations in all brain regions. The LC-MS techniques identified N-dealkylated FECNT as a major metabolite in the rat brain, and reverse-phase HPLC detected an equivalent amount of radiometabolite eluting with the void volume. The radiometabolite likely was 18F-fluoroacetaldehyde, the product expected from the N-dealkylation of 18F-FECNT, or its oxidation product, 18F-fluoroacetic acid. The distribution volume in the cerebellum increased up to 1.7-fold in humans between 60 and 300 min after injection and 2.0 +/- 0.1-fold (mean +/- SD; n = 3) in nonhuman primates between 60 and 240 min after injection.
An 18F-fluoroalkyl metabolite of 18F-FECNT originating in the periphery confounded the measurements of DAT in the rat brain with a reference tissue model. Its uniform distribution across brain regions suggests that it has negligible affinity for DAT (i.e., it is an inactive radiometabolite). Consistent with the rodent data, the apparent distribution volume in the cerebellum of both humans and nonhuman primates showed a continual increase at late times after injection, a result that may be attributed to entry of the radiometabolite into the brain. Thus, reference tissue modeling of 18F-FECNT will be prone to more errors than analysis with a measured arterial input function.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Positron emission tomography (PET) imaging has become a useful noninvasive technique to explore molecular biology within living systems; however, the utility of this method is limited by the availability of suitable radiotracers to probe specific targets and disease biology. Methods to identify potential areas of improvement in the ability to predict small molecule performance as tracers prior to radiolabeling would speed the discovery of novel tracers. In this retrospective analysis, we characterized the brain penetration, or peak SUV (standardized uptake value), binding potential (BP), and brain exposure kinetics across a series of known, non-radiolabeled PET ligands using in vivo LC-MS/MS (liquid chromatography coupled to mass spectrometry) and correlated these parameters with the reported PET ligand performance in non-human primates and humans available in the literature. The PET tracers studied included those reported to label G protein-coupled receptors (GPCRs), intracellular enzymes, and transporters. Additionally, data for each tracer was obtained from a mouse brain uptake assay (MBUA), previously published, where blood-brain barrier (BBB) penetration and clearance parameters were assessed and compared against similar data collected on a broad compound set of central nervous system (CNS) therapeutic compounds. The BP and SUV identified via non-radiolabelled LC-MS/MS, while different from the published values observed in the literature PET tracer data, allowed for an identification of initial criteria values we sought after in order to facilitate increased potential for success from our early discovery screening paradigm. Our analysis showed that successful, as well as novel, clinical PET tracers exhibited BP of greater than 1.5 and peak SUVs greater than approximately 150% at 5 minutes post dose in rodents. The brain kinetics appeared similar between both techniques despite differences in tracer dose, suggesting linearity across these dose ranges. The assessment of tracers in a CNS exposure model, the mouse brain uptake assessment (MBUA), showed that those compound with initial brain-to-plasma ratios > 2 and unbound fraction in brain homogenate > 0.01 were more likely to be clinically successful PET ligands. Taken together, early incorporation of a LC/MS/MS cold tracer discovery assay and a parallel MBUA can be an useful screening paradigm to prioritize and rank order potential novel PET radioligands during early tracer discovery efforts. Compounds considered for continued in vivo PET assessments can be identified quickly by leveraging in vitro affinity and selectivity measures, coupled with data from a MBUA, primarily the 5-minute brain-to-plasma ratio and unbound fraction data. Coupled utilization of these data creates a strategy to efficiently screen for the identification of appropriate chemical space to invest in for radiotracer discovery.
    ACS Chemical Neuroscience 09/2014; DOI:10.1021/cn500073j · 4.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: In vivo visualization of PDE10A using PET provides a tool to evaluate the role of PDE10A in various neuropsychiatric diseases and can also be useful in the clinical evaluation of PDE10A inhibitor drug candidates. We evaluated several carbon-11 and fluorine-18 labeled PDE10A inhibitors as potential PDE10A PET radioligands. Materials & Methods: [C-11]MP10, [C-11]JNJ42071965 and four other tracers were developed. Their biodistribution was evaluated in rats. Rat plasma and brain radiometabolites were quantified. Baseline microPET imaging was performed in normal rats and PDE10A knockout (KO) and wild-type (WT) mice. Blocking and displacement studies were conducted. The selectivity of the tracer binding was further studied in an ex vivo autoradiography experiment in PDE10A KO and WT mice. Results: Biodistribution showed brain uptake for all tracers in the striatum and wash-out from the cerebellum. [C-11](1) under bar (C-11-MP10) had the highest specific uptake index (striatum (S) vs. cerebellum
    Nuclear Medicine and Biology 05/2014; 41(8). DOI:10.1016/j.nucmedbio.2014.05.138 · 2.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The goals of the present thesis were to study high affinity agonist binding at the D 2 dopamine receptor and to explore the role of agonist induced internalization of the receptor in positron emission tomography (PET) imaging studies. For this purpose, we combined in vitro studies of radioligand binding and receptor internalization with in vivo studies in rodents using PET. A pharmacological characterization of the novel PET radioligand MNPA in vitro demonstrated that it is a potent and full agonist at the D 2 receptor. In membrane homogenates, MNPA bound to both a high and low affinity site of the D 2 receptor, of which the high affinity site was sensitive to guanosine triphosphate. In intact cells, however, MNPA bound to only one site of low affinity. As a typical agonist at G-protein coupled receptors, MNPA also induced receptor internalization, which was further augmented by arrestin proteins. [ 11 C]MNPA was evaluated as an agonist radioligand and used to measure the baseline occupancy of the D 2 dopamine receptors by dopamine. In vivo, [ 11 C]MNPA was a D 2 selective radioligand. Comparison of [ 11 C]MNPA binding in dopamine depleted rats and control rats suggested that about 50% of the D 2 receptors are occupied by dopamine at baseline. To study high affinity agonist binding in vivo, we compared the binding of [ 11 C]MNPA in control mice to that of dopamine--hydroxylase (DBH) knockout mice, which have been reported to exhibit an increased percentage of D 2 receptors in the high affinity state. The in vivo studies were accompanied by in vitro binding experiments in striatal membrane homogenates. We did not observe any differences in [ 11 C]MNPA BP ND between DBH knockout and control mice. Nor did we find any differences in density or percentage of D 2 receptors in high affinity state with in vitro binding experiments. Combined, this study suggests that DBH knockout mice have normal densities of D 2 receptors in the high affinity state. Agonist induced D 2 receptor internalization was evaluated using immunohistochemistry in striatal tissue slices from arrestin3 knockout and wild-type mice. Both dopamine and MNPA induced D 2 receptor internalization in wild-type tissue but not in knockout tissue. These results demonstrated that D 2 receptor internalization is mediated by arrestin3 and that the arrestin3 knockout mice can be used to study D 2 receptor internalization in vivo. To determine whether the prolonged decrease of radioligand binding after amphetamine is caused by receptor internalization, we imaged wild-type and arrestin3 knockout mice, which are incapable of internalizing D 2 receptors. The mice were imaged with both the D 2 agonist [ 11 C]MNPA and the D 2 antagonist [ 18 F]fallypride. The effect of amphetamine on radioligand binding was examined at two time points; 30 min and 4 hours post-amphetamine. At 30 min, [ 11 C]MNPA showed greater displacement than [ 18 F]fallypride, but each radioligand gave similar displacement in knockout and wild-type mice. At 4 hours, the binding of both radioligands returned to baseline in knockout mice but remained decreased in wild-type mice. Our results suggest that the prolonged decrease of radioligand binding after amphetamine is primarily due to D 2 receptor internalization rather than dopamine displacement. In conclusion, the present thesis demonstrates that MNPA is a potent and full agonist at the D 2 dopamine receptor and binds in vitro to both a high and low affinity state of the D 2 receptor. We also demonstrated that arrestin3 mediates internalization of the D 2 dopamine receptor and that the prolonged in vivo decrease of radioligand binding after amphetamine is likely due to receptor internalization rather than dopamine displacement.


Available from
May 23, 2014